OMER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Omeros Corp (OMER) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this moment. The technical indicators are neutral, the financial performance is weak, and there are no strong positive catalysts in the short term. While analysts have raised price targets based on the approval of Yartemlea, the company's financials and stock trend suggest a cautious approach.
The MACD is negative and contracting, RSI is neutral at 48.731, and moving averages are converging, indicating no clear trend. Key support is at 10.749, and resistance is at 11.994. Pre-market price is slightly down by -0.09%, reflecting weak momentum.
H.C. Wainwright raised the price target to $40 from $20, citing the approval of Yartemlea as a critical inflection point. Hedge funds are significantly increasing their positions in the stock, with a 185,085.19% increase in buying activity over the last quarter.
No recent news or congress trading activity. Stock trend analysis shows a 70% chance of declining by -1.41% in the next day, -3.05% in the next week, and -5.25% in the next month. Financial performance is weak, with negative net income and EPS trends.
In Q3 2025, revenue remained at $0 with no growth YoY. Net income dropped to -$30.92M, down -4.08% YoY, and EPS declined to -0.47, down -16.07% YoY. Gross margin remains at 0%.
H.C. Wainwright maintains a Buy rating and raised the price target to $40 from $20, citing the approval of Yartemlea as a significant validation of Omeros' value. However, this optimism is not supported by strong financials or technical momentum.
